▁British 8.5859375
▁Bi 8.046875
ote 1.814453125
ch 0.12213134765625
▁Pl 6.47265625
c 2.451171875
' 4.91796875
s 0.0031585693359375
▁Can 8.4609375
cer 0.164306640625
▁D 1.447265625
rug 0.0171661376953125
▁Mar 9.4375
im 7.6640625
ast 0.0114288330078125
at 2.6941299438476562e-05
▁Sh 2.49609375
ows 0.0253143310546875
▁Promise 1.423828125
, 4.55078125
▁But 2.41015625
▁F 3.916015625
aces 1.7646484375
▁H 3.248046875
urd 0.01390838623046875
les 0.03948974609375
▁to 3.70703125
▁Be 5.16015625
come 1.021484375
▁a 1.154296875
▁Block 1.4375
b 0.0006690025329589844
uster 0.0008025169372558594
<0x0A> 0.1937255859375
<0x0A> 10.015625
B 1.75390625
rit 0.06732177734375
ish 0.0210418701171875
▁Bi 0.12115478515625
ote 0.00014841556549072266
ch 0.016143798828125
▁P 2.384765625
LC 0.00836944580078125
▁today 6.640625
▁announced 1.0029296875
▁positive 1.34375
▁results 0.6337890625
▁from 0.318115234375
▁a 0.65673828125
▁late 3.017578125
- 0.1607666015625
stage 0.0135345458984375
▁clin 1.4091796875
ical 0.0007538795471191406
▁trial 0.11236572265625
▁of 0.44091796875
▁its 0.386962890625
▁experimental 1.8232421875
▁cancer 0.477294921875
▁drug 0.1390380859375
▁Mar 1.1845703125
im 0.0041046142578125
ast 0.00013017654418945312
at 1.6689300537109375e-05
. 0.80126953125
▁The 0.90478515625
▁drug 1.490234375
▁uses 8.1328125
▁a 0.7490234375
▁novel 2.220703125
▁approach 1.3291015625
▁to 0.2161865234375
▁blocking 3.3984375
▁tum 2.169921875
or 0.3125
▁growth 0.377685546875
▁by 1.7626953125
▁in 1.5048828125
hib 0.01078033447265625
iting 0.0022335052490234375
▁en 3.0859375
zym 0.00014078617095947266
es 0.08349609375
▁that 0.88232421875
▁allow 3.83203125
▁cancer 0.56982421875
▁cells 0.134521484375
▁to 0.010498046875
▁in 5.41796875
va 0.0792236328125
de 0.00012004375457763672
▁surrounding 1.583984375
▁t 0.12274169921875
issues 0.826171875
. 0.45947265625
▁ 7.98828125
<0x0A> 6.2890625
<0x0A> 0.607421875
In 3.71875
▁a 1.6123046875
▁Ph 2.08203125
ase 0.000392913818359375
▁ 1.9951171875
3 0.22705078125
▁trial 0.646484375
▁of 1.4169921875
▁ 0.499755859375
3 1.8486328125
4 2.35546875
7 2.408203125
▁patients 0.2041015625
▁with 0.3125
▁advanced 1.09375
▁pan 2.408203125
cre 0.00014483928680419922
atic 0.01346588134765625
▁cancer 0.0980224609375
, 0.1588134765625
▁Mar 0.76806640625
im 0.0032711029052734375
ast 0.0014743804931640625
at 0.00787353515625
▁increased 3.576171875
▁median 1.6201171875
▁surv 0.287109375
ival 0.002239227294921875
▁time 1.67578125
▁from 1.841796875
▁ 0.13330078125
4 1.955078125
. 0.1402587890625
2 2.220703125
▁months 0.39990234375
▁to 0.48095703125
▁ 0.0469970703125
5 0.67626953125
. 0.0192108154296875
8 2.330078125
▁months 0.0200958251953125
, 1.4541015625
▁a 1.88671875
▁ 0.84375
3 0.6337890625
8 1.1513671875
% 0.634765625
▁improvement 0.67041015625
▁compared 4.0390625
▁to 0.51220703125
▁standard 2.224609375
▁chem 1.1064453125
other 0.0036029815673828125
apy 0.007556915283203125
▁alone 2.435546875
. 0.0802001953125
▁Pat 3.943359375
ients 0.0227508544921875
▁receiving 2.46875
▁the 1.70703125
▁drug 0.3974609375
▁also 0.5244140625
▁reported 2.6171875
▁improved 2.439453125
▁quality 0.1717529296875
▁of 0.0291900634765625
▁life 0.0025043487548828125
▁and 1.8623046875
▁fewer 1.869140625
▁side 0.51904296875
▁effects 0.0543212890625
▁compared 1.9228515625
▁to 0.06964111328125
▁chem 1.87890625
other 0.027496337890625
apy 0.0011663436889648438
. 1.0615234375
<0x0A> 0.86083984375
<0x0A> 0.045074462890625
" 2.775390625
Th 1.326171875
ese 0.002864837646484375
▁results 0.85400390625
▁show 2.779296875
▁the 2.8359375
▁potential 0.62060546875
▁for 1.6376953125
▁Mar 0.177734375
im 0.0010175704956054688
ast 0.00017559528350830078
at 0.0005779266357421875
▁to 0.193115234375
▁become 0.89990234375
▁an 1.2607421875
▁important 0.12225341796875
▁new 0.47021484375
▁treatment 0.513671875
▁option 1.26171875
▁for 0.0819091796875
▁patients 0.66943359375
▁with 0.11029052734375
▁this 3.384765625
▁dev 1.46484375
ast 0.00014412403106689453
ating 0.0007495880126953125
▁disease 0.2548828125
," 0.123779296875
▁said 0.25146484375
▁Dr 1.41796875
. 0.07891845703125
▁Jane 6.77734375
▁Smith 6.703125
, 0.136474609375
▁British 2.876953125
▁Bi 0.0108184814453125
ote 0.00023758411407470703
ch 0.004055023193359375
' 0.123046875
s 0.0005125999450683594
▁Chief 1.3671875
▁Medical 0.244384765625
▁Officer 0.01007080078125
, 2.77734375
▁in 0.28515625
▁a 0.060302734375
▁statement 0.544921875
. 0.15771484375
▁The 4.046875
▁company 1.0966796875
▁plans 1.208984375
▁to 0.0230865478515625
▁seek 2.2734375
▁regul 1.115234375
atory 0.001270294189453125
▁appro 0.01276397705078125
val 6.651878356933594e-05
▁for 1.0263671875
▁the 0.64404296875
▁drug 0.06072998046875
▁in 0.64404296875
▁the 0.6943359375
▁UK 3.94140625
▁and 0.75439453125
▁EU 2.947265625
▁based 4.05078125
▁on 0.01045989990234375
▁these 0.85107421875
▁results 0.27685546875
. 0.462158203125
<0x0A> 0.217529296875
<0x0A> 0.0205078125
However 0.880859375
, 0.0027637481689453125
▁industry 6.13671875
▁anal 0.669921875
yst 0.0009593963623046875
s 0.0219268798828125
▁ca 1.9443359375
ution 0.0007219314575195312
ed 2.345703125
▁that 0.04156494140625
▁Mar 0.9462890625
im 0.0016050338745117188
ast 0.0005660057067871094
at 0.0006098747253417969
▁still 2.6796875
▁faces 0.07440185546875
▁significant 0.404296875
▁hur 0.521484375
d 1.728534698486328e-05
les 8.821487426757812e-05
▁to 1.82421875
▁become 0.8505859375
▁a 0.004436492919921875
▁commercial 4.22265625
▁block 1.759765625
b 7.319450378417969e-05
uster 7.081031799316406e-05
. 0.40966796875
▁As 5.75
▁an 1.970703125
▁adj 7.57421875
unct 0.7099609375
ive 0.955078125
▁treatment 1.3740234375
, 1.0224609375
▁it 1.787109375
▁would 1.86328125
▁need 2.193359375
▁to 0.004543304443359375
▁be 0.76953125
▁used 1.48828125
▁in 0.345947265625
▁combination 0.312255859375
▁with 0.004566192626953125
▁chem 1.669921875
other 0.002010345458984375
apy 0.008270263671875
, 1.16796875
▁limit 4.265625
ing 0.0003139972686767578
▁its 0.19384765625
▁potential 0.501953125
▁as 2.75
▁a 0.03070068359375
▁stand 0.10357666015625
- 1.150390625
alone 0.0002663135528564453
▁drug 1.19921875
. 0.06256103515625
▁The 2.708984375
▁surv 6.85546875
ival 0.0003979206085205078
▁benefit 0.46044921875
, 6.34765625
▁while 0.18310546875
▁statist 0.923828125
ically 1.4662742614746094e-05
▁significant 0.003429412841796875
, 0.0060272216796875
▁is 0.68115234375
▁still 3.138671875
▁relatively 0.84130859375
▁mod 0.7333984375
est 5.4836273193359375e-06
. 1.28125
▁And 0.64208984375
▁with 3.828125
▁many 3.904296875
▁new 2.568359375
▁cancer 0.32177734375
▁dru 0.1474609375
gs 4.410743713378906e-06
▁coming 2.404296875
▁to 0.326416015625
▁market 0.049652099609375
, 0.59423828125
▁the 2.115234375
▁competition 2.00390625
▁will 1.3310546875
▁be 0.1636962890625
▁inten 1.65625
se 1.895427703857422e-05
. 0.1343994140625
<0x0A> 0.1287841796875
<0x0A> 0.1268310546875
The 3.427734375
▁biggest 5.33203125
▁challenge 0.481201171875
, 1.6982421875
▁though 1.3505859375
, 0.0007333755493164062
▁may 0.2568359375
▁be 0.0228729248046875
▁the 0.74658203125
▁complexity 6.3671875
▁and 2.18359375
▁cost 0.55029296875
▁of 0.0213470458984375
▁the 1.5751953125
▁large 9.28125
▁clin 1.3896484375
ical 0.00039696693420410156
▁tri 0.1773681640625
als 3.337860107421875e-06
▁needed 0.828125
▁to 0.030975341796875
▁test 3.951171875
▁Mar 1.0087890625
im 0.0010652542114257812
ast 0.0002899169921875
at 0.0004718303680419922
▁in 1.662109375
▁other 1.9541015625
▁types 1.3681640625
▁of 0.0012655258178710938
▁solid 6.71484375
▁tum 0.03778076171875
ors 0.034393310546875
, 1.490234375
▁like 4.51171875
▁breast 1.0751953125
, 1.337890625
▁colon 1.1357421875
, 0.32666015625
▁and 0.1605224609375
▁lung 0.1475830078125
▁can 1.6513671875
cers 0.0004024505615234375
. 0.042327880859375
▁Th 9.5703125
ous 0.31494140625
ands 0.0030117034912109375
▁of 0.021026611328125
▁patients 0.063720703125
▁would 0.52099609375
▁need 0.356201171875
▁to 0.0003998279571533203
▁be 0.020416259765625
▁en 0.484130859375
rolled 0.00010502338409423828
▁in 0.261962890625
▁random 4.62890625
ized 0.0010585784912109375
▁tri 0.76806640625
als 7.283687591552734e-05
▁across 4.5078125
▁many 2.650390625
▁countries 0.5224609375
, 0.529296875
▁at 3.216796875
▁a 0.50341796875
▁potential 3.140625
▁cost 0.0345458984375
▁of 0.055450439453125
▁over 2.443359375
▁$ 0.11846923828125
1 0.305908203125
0 1.3623046875
0 0.004070281982421875
▁million 0.00959014892578125
▁per 2.61328125
▁trial 1.5791015625
. 0.0322265625
<0x0A> 0.6689453125
<0x0A> 0.035552978515625
B 2.248046875
rit 0.0079803466796875
ish 0.0004734992980957031
▁Bi 0.0021686553955078125
ote 3.0159950256347656e-05
ch 0.0009636878967285156
▁has 1.921875
▁just 6.41796875
▁$ 2.890625
4 2.478515625
2 3.048828125
▁million 0.1868896484375
▁in 0.02093505859375
▁c 0.042144775390625
ash 5.0067901611328125e-06
▁res 1.3408203125
erves 2.396106719970703e-05
▁after 5.3671875
▁heavy 8.0703125
▁sp 1.92578125
ending 3.0994415283203125e-05
▁on 0.087890625
▁the 2.677734375
▁pan 2.33203125
cre 0.00038313865661621094
atic 0.0285491943359375
▁cancer 0.039886474609375
▁tri 2.705078125
als 6.23464584350586e-05
. 0.47119140625
▁The 1.1123046875
▁company 0.03326416015625
▁will 1.740234375
▁need 0.09344482421875
▁to 0.098388671875
▁for 9.640625
ge 0.00897979736328125
▁partners 0.322509765625
hips 0.01178741455078125
▁with 0.261474609375
▁larger 1.0703125
▁ph 0.184814453125
arma 0.00113677978515625
ce 0.042144775390625
ut 1.0371208190917969e-05
ical 8.26120376586914e-05
▁fir 1.876953125
ms 7.271766662597656e-06
▁to 0.58837890625
▁fin 1.8603515625
ance 0.00017511844635009766
▁additional 3.427734375
▁studies 2.380859375
, 2.080078125
▁but 1.935546875
▁may 3.232421875
▁have 1.494140625
▁to 2.783203125
▁sacrifice 4.04296875
▁a 2.232421875
▁considerable 5.94140625
▁share 1.806640625
▁of 0.0299072265625
▁future 2.0078125
▁prof 0.8359375
its 0.00014770030975341797
▁in 0.8818359375
▁the 1.3544921875
▁process 0.04791259765625
. 0.0084228515625
<0x0A> 0.202392578125
<0x0A> 0.04296875
Some 4.69921875
▁anal 0.69970703125
yst 6.67572021484375e-05
s 9.059906005859375e-05
▁argue 3.6171875
▁that 0.0209503173828125
▁Mar 1.103515625
im 0.0008931159973144531
ast 0.00022780895233154297
at 0.00024628639221191406
▁could 1.9130859375
▁still 0.7060546875
▁find 4.80859375
▁a 0.361328125
▁n 0.374755859375
iche 5.555152893066406e-05
, 5.47265625
▁especially 1.7841796875
▁if 1.5029296875
▁proven 5.3359375
▁effective 0.314208984375
▁for 3.134765625
▁patients 2.53125
▁with 0.5537109375
▁certain 2.279296875
▁bi 6.1953125
om 0.032257080078125
ark 0.00010836124420166016
ers 0.02294921875
▁or 0.49560546875
▁in 2.40625
▁combination 0.447021484375
▁with 0.073486328125
▁other 0.118896484375
▁dru 0.79248046875
gs 4.887580871582031e-06
. 0.0986328125
▁The 2.869140625
▁most 5.6875
▁likely 2.658203125
▁partners 4.875
▁would 2.435546875
▁be 0.050750732421875
▁major 2.77734375
▁on 3.380859375
col 0.006633758544921875
ogy 4.0650367736816406e-05
▁players 1.03125
▁like 0.322998046875
▁A 2.5546875
stra 0.020751953125
Z 0.01499176025390625
en 0.0006852149963378906
eca 0.0008411407470703125
, 0.94677734375
▁Gla 3.271484375
x 0.00022649765014648438
o 0.0006775856018066406
Smith 0.006610870361328125
K 0.0010805130004882812
line 0.00043010711669921875
, 0.056304931640625
▁and 1.41796875
▁Mer 2.74609375
ck 0.0002791881561279297
. 1.8427734375
<0x0A> 0.609375
<0x0A> 0.04058837890625
For 4.19140625
▁now 0.4990234375
, 0.0073699951171875
▁British 0.88427734375
▁Bi 0.0009469985961914062
ote 3.4570693969726562e-06
ch 0.00029921531677246094
▁has 3.98046875
▁cleared 8.6640625
▁an 1.9013671875
▁important 0.321044921875
▁hur 0.26904296875
d 1.3113021850585938e-06
le 0.0001468658447265625
, 2.142578125
▁but 0.410400390625
▁the 0.58740234375
▁road 1.4228515625
▁ahead 0.55322265625
▁remains 1.1591796875
▁long 0.724609375
. 5.4296875
▁With 4.4765625
▁science 8.3515625
▁on 4.59765625
▁their 0.93505859375
▁side 0.0011301040649414062
▁but 4.1796875
▁money 2.037109375
▁in 2.05859375
▁short 0.10650634765625
▁supply 0.0007076263427734375
, 0.0030975341796875
▁the 0.92333984375
▁company 0.370361328125
▁will 0.62451171875
▁have 1.6826171875
▁to 0.034515380859375
▁run 4.234375
▁a 0.4375
▁ga 3.158203125
unt 0.00023436546325683594
let 2.5272369384765625e-05
▁of 0.060394287109375
▁financial 2.923828125
, 1.5703125
▁clin 3.0
ical 0.00010418891906738281
, 0.06158447265625
▁and 0.036376953125
▁commercial 3.603515625
▁challeng 0.27880859375
es 4.2438507080078125e-05
▁to 0.92236328125
▁turn 2.00390625
▁their 2.3203125
▁prom 0.91748046875
ising 6.020069122314453e-05
▁new 2.478515625
▁drug 0.187255859375
▁into 0.004367828369140625
▁a 0.06817626953125
▁sust 5.34375
ain 0.0155029296875
able 0.0013103485107421875
▁business 0.2493896484375
. 0.0869140625
▁Pat 11.703125
ients 0.25390625
▁and 1.7451171875
▁invest 0.213623046875
ors 0.00010406970977783203
▁al 0.321533203125
ike 1.6808509826660156e-05
▁will 0.158447265625
▁be 0.07098388671875
▁following 5.92578125
▁closely 1.1103515625
▁to 0.401123046875
▁see 0.00597381591796875
▁if 0.433837890625
▁Mar 1.552734375
im 0.0011615753173828125
ast 0.00012290477752685547
at 0.00034546852111816406
▁can 0.2232666015625
▁stay 6.32421875
▁the 1.9267578125
▁course 0.004364013671875
. 0.2205810546875
